Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGEN-001 in Colorectal Peritoneal Carcinomatosis
NCT01300858Phase 2Terminated
- Sponsor
- EGEN
- Start
- Jun 2011
- Primary completion
- Jul 2014
- Modality
- Gene Editing, Nanoparticles, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IMNN-001 in colorectal cancer (CRC), sponsored by EGEN. Primary endpoints: Progression-free survival at 5 years, Overall survival at 5 years and 1 more. Started Jun 2011; status: terminated.
02
Drugs
IMNN-001
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01300858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01300858.